论文信息 - Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC - 字舞流文

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Daniel T. Fisher | P. Wallace | I. Puzanov | K. Leon | M. Ernstoff | M. Opyrchal | Kelvin P Lee | G. Dy | K. Attwood | A. Lage | T. Crombet | M. Reid | Z. Mazorra | D. Saavedra | C. Mesa | R. Evans | P. Luaces | J. Muhitch | A. Groman | C. Fountzilas | T. Dai | Askia Dozier | C. Johnson | Alan Hutson | Orestes Santos-Morales | Carlos Cedeno | Aileen Cinquino | Alan D. Hutson | A. Dozier | D. Fisher | Kelvin P. Lee